129 related articles for article (PubMed ID: 32266817)
1. Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review.
Shao F; Zhang H; Yang X; Luo X; Liu J
Neoplasma; 2020 Jul; 67(4):715-723. PubMed ID: 32266817
[TBL] [Abstract][Full Text] [Related]
2. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
4. The safety of apatinib for the treatment of gastric cancer.
Geng R; Song L; Li J; Zhao L
Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
[TBL] [Abstract][Full Text] [Related]
5. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
6. Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours.
Liu G; Wang C; He Y; E M
BMC Pharmacol Toxicol; 2019 Oct; 20(1):61. PubMed ID: 31661009
[TBL] [Abstract][Full Text] [Related]
7. Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.
Wang Y; Bi M; Zhang H; Gao Z; Zhou H; Chang S
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e528-e530. PubMed ID: 28028915
[TBL] [Abstract][Full Text] [Related]
8. Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial.
Zhou JG; Zhou NJ; Zhang Q; Feng YY; Zhou H
Trials; 2018 Sep; 19(1):500. PubMed ID: 30223869
[TBL] [Abstract][Full Text] [Related]
9. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
Liu X; Xu J; Li F; Liao Z; Ren Z; Zhu L; Shi Y; Zhao G; Bai X; Zhao J; Xing R; Teng S; Yang Y; Yang J
Biomed Pharmacother; 2020 Feb; 122():109587. PubMed ID: 31786466
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma.
Liu G; Wang Y; Wang C; He Y; E M
Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1423-1430. PubMed ID: 33115264
[No Abstract] [Full Text] [Related]
12. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Fathi Maroufi N; Rashidi MR; Vahedian V; Akbarzadeh M; Fattahi A; Nouri M
Life Sci; 2020 Jan; 241():117106. PubMed ID: 31786193
[TBL] [Abstract][Full Text] [Related]
14. Apatinib for the treatment of gastric cancer.
Geng R; Li J
Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
[TBL] [Abstract][Full Text] [Related]
15. Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma.
Zeng DX; Lei W; Wang CG; Huang JA; Jiang JH
Cancer Chemother Pharmacol; 2019 Mar; 83(3):439-442. PubMed ID: 30547193
[TBL] [Abstract][Full Text] [Related]
16. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
[TBL] [Abstract][Full Text] [Related]
17. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.
Zhang D; Zhang C; Huang J; Guan Y; Guo Q
Thorac Cancer; 2018 Dec; 9(12):1754-1762. PubMed ID: 30338916
[TBL] [Abstract][Full Text] [Related]
18. Progress in the treatment of solid tumors with apatinib: a systematic review.
Zhao D; Hou H; Zhang X
Onco Targets Ther; 2018; 11():4137-4147. PubMed ID: 30050305
[TBL] [Abstract][Full Text] [Related]
19. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
[TBL] [Abstract][Full Text] [Related]
20. Apatinib-induced hyperammonemic encephalopathy.
Liu Y; Chen X; Gao X; Chen JX; Chen J
J Oncol Pharm Pract; 2020 Mar; 26(2):465-470. PubMed ID: 31068089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
